BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/6/2017 3:54:00 PM | Browse: 1303 | Download: 2201
 |
Received |
|
2016-11-22 11:19 |
|
Peer-Review Started |
|
2016-11-23 15:07 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2016-12-15 13:50 |
|
Revised |
|
2016-12-19 08:32 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2017-01-04 16:10 |
|
Second Decision by Editor-in-Chief |
|
2017-01-05 19:29 |
|
Final Decision by Editorial Office Director |
|
2017-01-14 14:18 |
|
Articles in Press |
|
2017-01-14 14:19 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-03-02 15:21 |
|
Publish the Manuscript Online |
|
2017-03-06 15:54 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Basic Study |
| Article Title |
Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Preeyanat Vongchan and Robert J Linhardt |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Research Council of Thailand (NRCT) |
2559A10402115 |
|
| Corresponding Author |
Preeyanat Vongchan, PhD, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, 239 Huay Kaew Road, Muang District, Chiang Mai 50200, Thailand. preeyanat.v@cmu.ac.th |
| Key Words |
Monoclonal anti-glypican-3; Hepatocellular carcinoma; HepG2; Heparan sulfate proteoglycan; Co-immunoprecipitation |
| Core Tip |
Heparan sulfate proteoglycan (HSPG) was isolated from human liver. Preliminary results showed that it was detected by rabbit anti-glypican. Monoclonal antibody, 1E4-1D9 was raised against human liver HSPG and its specific antigen was characterized. Amino acid sequence analysis revealed that the antigen recognized by mAb 1E4-1D9 specific molecule contained no trans-membrane region. It has 15 cysteines and 11 putative glycosylation sites and 6 predicted N-glycosylation sites. The sequence matched to all PDZ domain proteins with an 85.6% match to glypican-3. Studies of co-ex-pression and co-precipitation demonstrated that mAb 1E4-1D9 could compete with anti-glypican-3. It could also react with a various tumor cell lines including solid and hematopoietic cells. The findings suggested that the antigen recognized by 1E4-1D9 was glypican-3. Moreover, findings revealed that FYCO1 co-precipitated with glypican-3 using mAb 1E4-1D9, suggesting that FYCO1 is a partner molecule of glypican-3. |
| Publish Date |
2017-03-06 15:54 |
| Citation |
Vongchan P, Linhardt RJ. Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2. World J Hepatol 2017; 9(7): 368-384 |
| URL |
http://www.wjgnet.com/1948-5182/full/v9/i7/368.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v9.i7.368 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
